{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T20:53:54Z","timestamp":1778187234049,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100018696","name":"R\u00e9gion Normandie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018696","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.pharma.2025.01.013","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T01:50:30Z","timestamp":1738288230000},"page":"690-697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of advanced therapy medicinal products status in European regulations on their production cost: The case of hematopoietic stem cells"],"prefix":"10.1016","volume":"83","author":[{"given":"Thibault","family":"Cousin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Chantreuil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5300-6244","authenticated-orcid":false,"given":"Eric","family":"Barat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Norol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9mi","family":"Varin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Lebon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Giverne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.pharma.2025.01.013_bib0145","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.pharma.2025.01.013_bib0150","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2025.01.013_bib0155","unstructured":"European parliament, C.o.t.E.U., DIRECTIVE 2001\/83\/EC of 6 November 2001 on the Community code relating to medicinal products for human use, in Official Journal of the European Communities. 2001. p.\u00a067\u2013128."},{"key":"10.1016\/j.pharma.2025.01.013_bib0160","unstructured":"European parliament, C.o.t.E.U., REGULATION (EC) No.\u00a01394\/2007 OF of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001\/83\/EC and Regulation (EC) No 726\/2004 (Text with EEA relevance), in Official Journal of the European Union. 2007. p.\u00a0121\u201337."},{"key":"10.1016\/j.pharma.2025.01.013_bib0165","unstructured":"European parliament, C.o.t.E.U., DIRECTIVE 2004\/23\/EC of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells, in Official Journal of the European Union. 2004. p.\u00a048\u201358."},{"key":"10.1016\/j.pharma.2025.01.013_bib0170","unstructured":"Alliance for Regenerative Medicine. Growth & Resilience in Regenerative Medicine \u2013 Annual Report. Washington, D.C: ARM; 2020."},{"key":"10.1016\/j.pharma.2025.01.013_bib0175","doi-asserted-by":"crossref","unstructured":"Aguilera-Cobos L, et al. Barriers for the evaluation of advanced therapy medicines and their translation to clinical practice: Umbrella review, Health policy, 2022, p.\u00a01248\u201355.","DOI":"10.1016\/j.healthpol.2022.10.007"},{"key":"10.1016\/j.pharma.2025.01.013_bib0180","unstructured":"Human Medicines Highlights 2022, EMA, 2023, human-medicines-highlights-2022_en.pdf (europa.eu)."},{"key":"10.1016\/j.pharma.2025.01.013_bib0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.omtm.2018.10.003","article-title":"Challenges in advanced therapy medicinal product development: a survey among companies in Europe","volume":"11","author":"Ten Ham","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"10.1016\/j.pharma.2025.01.013_bib0190","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1089\/humc.2016.193","article-title":"Clinical development and commercialization of advanced therapy medicinal products in the European Union: how are the product pipeline and regulatory framework evolving?","volume":"28","author":"Boran","year":"2017","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.pharma.2025.01.013_bib0195","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3389\/fmed.2017.00182","article-title":"Regulatory and scientific advancements in gene therapy: state-of-the-art of clinical applications and of the supporting European Regulatory Framework","volume":"4","author":"Carvalho","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.pharma.2025.01.013_bib0200","unstructured":"Alili JM, et al. M\u00e9dicament de th\u00e9rapie innovante\u00a0: cadre r\u00e9glementaire et application th\u00e9rapeutique. Dossier du CNHIM, 2017(tome XXXVIII, 1): p.\u00a03\u201363."},{"issue":"7","key":"10.1016\/j.pharma.2025.01.013_bib0205","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jcyt.2016.03.292","article-title":"Cell-based product classification procedure: What can be done differently to improve decisions on borderline products?","volume":"18","author":"Izeta","year":"2016","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.pharma.2025.01.013_bib0210","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40259-015-0140-7","article-title":"Sipuleucel-T (Provenge\u00ae)-Autopsy of an innovative paradigm change in cancer treatment: why a single-product biotech company failed to capitalize on its breakthrough invention","volume":"29","author":"Jaroslawski","year":"2015","journal-title":"BioDrugs"},{"issue":"5","key":"10.1016\/j.pharma.2025.01.013_bib0215","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5500\/wjt.v11.i5.138","article-title":"Transplantation of CD34+ cells for myocardial ischemia","volume":"11","author":"Matta","year":"2021","journal-title":"World J Transplant"},{"issue":"8","key":"10.1016\/j.pharma.2025.01.013_bib0220","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1161\/CIRCRESAHA.116.304386","article-title":"Meta-analysis of cell therapy trials for patients with heart failure","volume":"116","author":"Fisher","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.pharma.2025.01.013_bib0225","unstructured":"Pierrons JP, Vinot D, Chelle E. Les valeurs du soin\/enjeux \u00e9thiques, \u00e9conomiques et politiques. 2008. p.\u00a0192."},{"key":"10.1016\/j.pharma.2025.01.013_bib0230","doi-asserted-by":"crossref","unstructured":"International Monetary Fund, France, At a glance. 2023. https:\/\/www.imf.org\/en\/Countries\/FRA.","DOI":"10.5089\/9798400232336.002"},{"key":"10.1016\/j.pharma.2025.01.013_bib0235","unstructured":"ANSM, D\u00e9cision du 5 mai 2017 modifiant la d\u00e9cision du 27 octobre 2010 d\u00e9finissant les r\u00e8gles de bonnes pratiques relatives \u00e0 la pr\u00e9paration, \u00e0 la conservation, au transport, \u00e0 la distribution et \u00e0 la cession des tissus, des cellules et des pr\u00e9parations de th\u00e9rapie cellulaire. 2017. https:\/\/www.ansm.sante.fr\/Activites\/Elaboration-de-bonnes-pratiques\/Bonnes-pratiques-Tissus-et-Cellules."},{"key":"10.1016\/j.pharma.2025.01.013_bib0240","unstructured":"Commission E. Guidelines on Good Manufacturing Practice (GMP) specific to Advanced Therapy Medicinal Products (ATMP). 2017, Health and Food Safety Directorate General."},{"key":"10.1016\/j.pharma.2025.01.013_bib0245","unstructured":"ANSM. Guide des bonnes pratiques de fabrication. https:\/\/ansm.sante.fr\/uploads\/2023\/02\/01\/20230201-guide-bpf-2022.pdf, 2022."},{"key":"10.1016\/j.pharma.2025.01.013_bib0250","unstructured":"Agence de la Biom\u00e9decine. https:\/\/rams.agence-biomedecine.fr\/activite-du-registre-eurocord-0, 2024."},{"issue":"11","key":"10.1016\/j.pharma.2025.01.013_bib0255","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.bbmt.2006.06.011","article-title":"Microbial contamination of hematopoietic stem cell products: incidence and clinical sequelae","volume":"12","author":"Klein","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.pharma.2025.01.013_bib0260","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbmt.2018.08.003","article-title":"Prospective evaluation of a practical guideline for managing positive sterility test results in cell therapy products","volume":"25","author":"Panch","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.pharma.2025.01.013_bib0265","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1111\/trf.12150","article-title":"Microbial contamination of hematopoietic progenitor and other regenerative cells used in transplantation and regenerative medicine","volume":"53","author":"Jacobs","year":"2013","journal-title":"Transfusion"},{"issue":"8","key":"10.1016\/j.pharma.2025.01.013_bib0270","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jhin.2021.04.006","article-title":"Prevalence and significance of bacterial contamination of autologous stem cell products","volume":"114","author":"Damonti","year":"2021","journal-title":"J Hosp Infection"},{"key":"10.1016\/j.pharma.2025.01.013_bib0275","unstructured":"Maresso A, et al. Economic crisis, health systems and health in Europe: Country experience. 2015. European Observatory Health Policy Series."},{"key":"10.1016\/j.pharma.2025.01.013_bib0280","doi-asserted-by":"crossref","DOI":"10.1186\/s40545-016-0057-7","article-title":"Navigating through the maze of pricing and affordability of branded pharmaceuticals in the midst of the financial crisis: a comparative study among five European recession countries, from a Cyprus perspective","volume":"9","author":"Petrou","year":"2016","journal-title":"J Pharm Policy Pract"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450925000136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450925000136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T12:59:20Z","timestamp":1749905960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450925000136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0003450925000136"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2025.01.013","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of advanced therapy medicinal products status in European regulations on their production cost: The case of hematopoietic stem cells","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2025.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}